Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

European Funding Boosts Research into Breast Cancer

29.04.2005


As cancer is the main cause of death among women aged 35 to 64 the EU’s Sixth Framework Programme (FP6) has agreed to provide seven million euros for a new Network of Excellence called TRANS-BIG, aimed at addressing the treatment of breast cancer.



TRANS-BIG aims to refine the diagnosis of breast cancer in a way that will enable specialists reduce the number of women being over treated by better identification of those who will benefit from treatment.

“Under the present system many patients are over treated while only a few derive a considerable benefit”, says Dr Robert Leonard from the South West Wales Cancer Institute. “By refining the prognosis for a better definition of who needs treatment we hope to significantly reduce the proportion of women receiving unnecessary chemotherapy and reduce their exposure to toxicity and harmful long-term side effects. At the same time, this will considerably reduce the cost of breast cancer therapy and its burden on European health care systems.


“Indeed, two decades of clinical trials have shown that although chemotherapy increases the survival rate from 2 to 12 per cent, it can also be the cause of secondary cancers, cardiac toxicity, early menopause and a reduction in cognitive functions.”

The TRANS-BIG Network of Excellence, based on the principles of translational research - ’bench to bedside’ and ’bedside to bench’ - will tackle the fragmentation which currently exists in this field of research and accelerate the clinical applications of biological discoveries.

With 39 partners from 21 countries the TRANS-BIG consortium has the critical mass expertise needed to create a fully coherent research force of leading specialists in Europe. This in itself will help overcome the existing fragmentation of effort and give Europe the competitive approach it needs to take the lead in breast cancer therapy internationally.

The first target of TRANS-BIG is the development of its first trial - MINDACT (Microarray for Node Negative Disease may avoid Chemotherapy) - using microarrays to identify the specific molecular make up (’signature’) of a tumour. Although still in its infancy, this technology is expected to allow for a better selection of the patients that actually do need chemotherapy.

“We believe that the results of MINDACT will show that using the new technology to assess risk will result in fewer women being treated unnecessarily”, added Dr Leonard. “This, in turn, will mean that fewer women will suffer from the unpleasant side effects of chemotherapy. Not only will the overall quality of life of breast cancer patients be improved, but the health care costs associated with such cancer treatment will be reduced as well, thus providing a significant benefit to society. Additionally, by more accurately choosing patients who do need chemotherapy the final outcome in terms of survival is expected to be better.

By conducting translational research in an integrated way, the project will ensure that the best facilities from the leading cancer research and treatment institutes will be shared, thus decreasing cost and increasing effectiveness.

“Improving the way we diagnose and treat breast cancer is crucial if we are to prevent many women receiving unnecessary, and costly, chemotherapy treatment in the future”, says Claire Horton, FP6UK’s National Contact Point for ’Life sciences, genomics and biotechnology for health. “The fight against cancer is a priority issue for the EU as it is estimated that our increasingly ageing population will lead to an extra 250,000 cancer diagnoses every year in Europe by 2020.

“The current Framework Programme (FP6) runs until 2006 and organisations wanting free information on how to access some of the 19 billion euros available should log on to http://fp6uk.ost.gov.uk or call central telephone support on 0870 600 6080.”

Dave Sanders | alfa
Further information:
http://fp6uk.ost.gov.uk

More articles from Health and Medicine:

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Better equipped in the fight against lung cancer
16.05.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

Im Focus: Computer-Designed Customized Regenerative Heart Valves

Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.

Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...

Im Focus: Light-induced superconductivity under high pressure

A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.

Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Supersonic waves may help electronics beat the heat

18.05.2018 | Power and Electrical Engineering

Keeping a Close Eye on Ice Loss

18.05.2018 | Information Technology

CrowdWater: An App for Flood Research

18.05.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>